IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

iBio Inc.

iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates.

IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike protein fused with the company’s patented lichenase booster molecule (LicKM).

iBio completed 10 distinct preclinical study arms testing various antigen-adjuvant combinations. Anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization and continued to increase over the 42-day study, generating favorable helper T-cell immune profiles. 

In addition, early ex vivo testing of antisera from IBIO-201-immunized mice demonstrated the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2.

“We are encouraged by these preclinical data, which demonstrate IBIO-201’s ability to generate an immune response to SARS-CoV-2 sequences and neutralize protein interaction,” Tom Isett, iBio’s chairman and CEO, said in a statement.

The company plans to conduct additional testing of IBIO-201 antisera, including further evaluations of neutralizing titers and immune profiling studies. 

“We expect to gain more insight as we complete data analysis of both of our COVID-19 vaccine candidates,” he added. 

Additional testing for both IBIO-201 and IBIO-200 is occurring in collaboration with the Texas A&M University System laboratories.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.